Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18: all 71 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)CompletedNCT03493542Phase 3Results posted
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®CompletedNCT02993757Phase 3Results posted
• Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital WartsCompletedNCT02750202Phase 3Results posted
• Safety and Tolerability Study of V501 in Japanese Boys (V501-200)CompletedNCT02576054Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsCompletedNCT02199691Phase 2Results posted
• Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)CompletedNCT01862874Phase 3Results posted
• Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus PatientsCompletedNCT01741012Phase 1Results posted
• V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)CompletedNCT01544478Phase 4Results posted
• Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer SurvivorsCompletedNCT01492582Phase 2Results posted
• Preparedness Study - HPV VaccineCompletedNCT01489527Not applicableResults posted
• Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old FemalesCompletedNCT01462357Phase 3Results posted
• A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17CompletedNCT01461993Phase 2Results posted
• Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and WomenCompletedNCT01461096Phase 3Results posted
• Study of Gardasil in Mid-Adult Males (MAM)CompletedNCT01432574Phase 2Results posted
• GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)CompletedNCT01245764Phase 3Results posted
• Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With MalesCompletedNCT01209325Phase 2Results posted
• Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University SettingCompletedNCT01184079Not applicableResults posted
• Gardasil Vaccination in Post Stem Cell Transplant PatientsCompletedNCT01092195Phase 1Results posted
• The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With CondylomataCompletedNCT00941889Not applicableResults posted
• Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex WorkersCompletedNCT00925288Phase 4Results posted
• Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in IndiaActive, not recruitingNCT00923702Phase 4Results posted
• Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)CompletedNCT00834106Phase 3Results posted
• A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young AdultsTerminatedNCT00798265Phase 1Results posted
• Immunogenicity and Safety of HPV Vaccine Gardasil in Young WomenCompletedNCT00786409Not applicableResults posted
• Vaccine Therapy in Preventing HPV in HIV-Positive Women in IndiaCompletedNCT00667563Phase 1Results posted
• An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)CompletedNCT00635830Phase 1Results posted
• Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected WomenCompletedNCT00604175Phase 2Results posted
• Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University SettingCompletedNCT00572832Not applicableResults posted
• Immunogenicity and Reactogenicity of Alternative Schedules of GardasilCompletedNCT00524745Not applicableResults posted
• Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 InfectionCompletedNCT00513526Phase 2Results posted
• An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)CompletedNCT00496626Phase 3Results posted
• V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)CompletedNCT00411749Phase 2Results posted
• Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)CompletedNCT00380367Phase 3Results posted
• V501 Efficacy Study in Women Aged 18 to 26 (V501-027)CompletedNCT00378560Phase 2Results posted
• Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)CompletedNCT00365716Phase 2Results posted
• Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)CompletedNCT00365378Phase 2Results posted
• Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected ChildrenCompletedNCT00339040Phase 2Results posted
• Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)CompletedNCT00157950Phase 3Results posted
• A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)CompletedNCT00092547Phase 3Results posted
• Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)CompletedNCT00092521Phase 3Results posted
• Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)CompletedNCT00092495Phase 3Results posted
• An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)CompletedNCT00090285Phase 3Results posted
• A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)CompletedNCT00090220Phase 3Results posted
• A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in ZambiaActive, not recruitingNCT07256912Phase 4
• Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital WartsStatus unknownNCT05761002Not applicable
• Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive AdolescentsCompletedNCT05435209Phase 4
• Gardasil Versus Cervarix in the Treatment of WartsCompletedNCT05383625Phase 3
• A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 YearsStatus unknownNCT05060484Phase 2
• Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical CancerStatus unknownNCT04096911Phase 2
• Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9CompletedNCT03431246Phase 3
• Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic ResponseStatus unknownNCT03296397Phase 3
• FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening ProgramCompletedNCT03105856Phase 4
• Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant RecipientsCompletedNCT02624349Phase 4
• Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico CityStatus unknownNCT02382900Phase 3
• Immunogenicity of HPV Vaccine in Immunosuppressed ChildrenCompletedNCT02263703Phase 3
• HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN)CompletedNCT02087384Phase 4
• ICI-VPH: Impact of HPV Immunisation Schedules Against HPVCompletedNCT02009800Phase 3
• 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in ChildrenStatus unknownNCT01995721Phase 3
• Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)CompletedNCT01914367Phase 4
• Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young AdultsStatus unknownNCT01512784Phase 3
• Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected AdultsCompletedNCT01386164Phase 4
• The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, PeruCompletedNCT01338051Phase 1
• A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot StudyStatus unknownNCT01133509Not applicable
• Mother - Daughter Initiative (MDI) in Cervical Cancer PreventionCompletedNCT01096134Not applicable
• Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in ChinaStatus unknownNCT01021904Phase 4
• Reactogenicity Study of Cervarix and Gardasil in UK Adolescent GirlsCompletedNCT00956553Phase 4
• Measuring Responses to Sublingual AntigensCompletedNCT00949572Not applicable
• Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled StudyCompletedNCT00911521Phase 4
• Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)WithdrawnNCT00733122Phase 3
• Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant RecipientsCompletedNCT00677677Phase 3
• Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected MenStatus unknownNCT00666107Not applicable

← Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 overview